Cetus said it was awarded five more patents.

The Emeryville, Calif.-based biotechnology company said one of the patents was its third in interleukin-2, a protein that has shown promise as a potential treatment for cancer. The other patents were for a hybrid protein of interferon, also cited as a potential treatment for cancer and infectious diseases, and an enzyme and related methods involving the production of fructose, a form of sugar.